Navigation Links
Schering-Plough Initiates Phase II Study With Vicriviroc in Treatment-Naive HIV-Infected Patients
Date:4/15/2008

Novel Nucleoside-Sparing Regimen Designed to Avoid Risk of Toxicity

Associated with Nucleoside Class of HIV Drugs

KENILWORTH, N.J., April 15 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP) today announced that it has initiated a Phase II clinical study with vicriviroc, its investigational CCR5 antagonist, for use in first-line therapy of adult treatment-naive HIV-infected patients with R5-type virus only. Vicriviroc is a next-generation HIV entry inhibitor designed to prevent the virus from infecting CD4 cells by blocking its predominant entry route, the CCR5 co-receptor. Approximately 80-90 percent of treatment-naive patients have virus that uses the CCR5 co-receptor.(1) Vicriviroc also is being studied in two large Phase III clinical studies in treatment-experienced HIV patients, which are ongoing and currently enrolling patients.

The study in treatment-naive patients evaluates the virologic benefit of vicriviroc, administered once-daily as a single 30 mg tablet, in combination with ritonavir-boosted atazanavir,(2) compared to a control group receiving Truvada (emtricitabine and tenofovir disoproxil fumarate)(3) plus ritonavir- boosted atazanavir, which is a currently recommended option for first-line therapy. Atazanavir is a product in the protease inhibitor (PI) class of HIV medications. Truvada is a combination product in the nucleoside reverse transcriptase inhibitor (NRTI) class.

"A nucleoside-sparing vicriviroc regimen for initial treatment may have the added strategic benefit of preserving most products used to create a highly active antiretroviral therapy "cocktail" for later use in patients, while also avoiding the risk of toxicity known to be associated with the nucleoside
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Parker Waichman Alonso LLP and Affiliated Lawfirms Have Filed a Class Action Lawsuit in the United States District Court for the Eastern District of New York Against Merck & Co., Inc. and Schering-Plough Corporation
2. Schering-Plough Reports Top-Line Results of the IDEAL Study
3. Schering-Plough Announces Asenapine NDA Accepted for Filing by the U.S. FDA
4. Schering-Plough Highlights PEGINTRON(TM) Clinical Data Presentations at the American Association for the Study of Liver Diseases (AASLD) 2007 Annual Meeting
5. Pharmacopeia Earns Milestone Payment From Schering-Plough on Initiation of Phase 1 Clinical Trials of Novel Therapeutic Candidate
6. Schering-Plough Initiates Phase III Studies with Vicriviroc in Treatment- Experienced HIV Patients
7. Texas Heart(R) Institute at St. Lukes Episcopal Hospital Initiates First Clinical Trial in the World to Treat a Heart Attack Patient with a Special Stem Cell Type
8. Kosan Initiates Phase 2 Trial of Epothilone KOS-1584 in Non-Small Cell Lung Cancer
9. Arena Pharmaceuticals Initiates Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
10. Trubion Initiates Phase 1/2 Study of TRU-016 in CLL, Announces Next-Generation Product Candidate for RA and Provides Product Pipeline Update
11. Repligen Initiates Phase 3 Clinical Trial of RG1068 for Pancreatic MRI Imaging

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/23/2009)..., ,, BOSTON,Nov.23/PRNewswire-FirstCall/-...mationmanagementsolutions,todayannouncedthatitwill...the2009RadiologicalSocietyofNorthAmerica(RSNA)annu...CASwillbeintheNorthHallinbooth#7124. ,, (Logo: ...SLOGO ) ,, "Giventhenationalconversationabouthe...
(Date:11/23/2009)..., NEWYORK,Nov.23/PRNewswire/--Reportlinker.coma...tscatalogue. ,, MedicalNonwovenDisposables-AWo...er.com/p0164292/Medical-Nonwoven-Disposables---A-W...amp;utm_medium=pr&utm_campaign=prnewswire ...gulationsputintoeffectinhealthcareandhospitalfacil...
(Date:11/23/2009)..., BIRMINGHAM,Ala.andNOIDA,India,Nov.23/PRNewswi...labamaatBirmingham(UAB),andSouthernResearchInstitu...gingtheircollectiveinnovationandenablingtechnologi...usDiseases.ItisauniqueU.S.-Indiaarbitragedandlever...ffordabletherapiesforpatientsworldwide.AMemorandum...
Breaking Medicine Technology:AMICAS' Enterprise Imaging Solutions Highlighted at RSNA 2009 2AMICAS' Enterprise Imaging Solutions Highlighted at RSNA 2009 3Reportlinker Adds Medical Nonwoven Disposables - A Worldwide Market Review 2Reportlinker Adds Medical Nonwoven Disposables - A Worldwide Market Review 3Reportlinker Adds Medical Nonwoven Disposables - A Worldwide Market Review 4Reportlinker Adds Medical Nonwoven Disposables - A Worldwide Market Review 5Reportlinker Adds Medical Nonwoven Disposables - A Worldwide Market Review 6Reportlinker Adds Medical Nonwoven Disposables - A Worldwide Market Review 7Reportlinker Adds Medical Nonwoven Disposables - A Worldwide Market Review 8Jubilant Organosys, UAB and Southern Research Enter Into Drug Discovery Joint Venture 2Jubilant Organosys, UAB and Southern Research Enter Into Drug Discovery Joint Venture 3Jubilant Organosys, UAB and Southern Research Enter Into Drug Discovery Joint Venture 4Golden Meditech Announces HK 24217 Million Private Equity Financing for Hospital Subsidiary 14309 1Golden Meditech Announces HK 24217 Million Private Equity Financing for Hospital Subsidiary 14309 2Spectrum Announces Support Partnership for Breast Cancer Research During Breast Cancer Awareness Month 14307 1Spectrum Announces Support Partnership for Breast Cancer Research During Breast Cancer Awareness Month 14307 2Spectrum Announces Support Partnership for Breast Cancer Research During Breast Cancer Awareness Month 14307 3BioSpace Launches the 2010 Biotech Beach Hotbed Campaign 58625 1BioSpace Launches the 2010 Biotech Beach Hotbed Campaign 58625 2
(Date:11/23/2009)...n.,Nov.23/PRNewswire/--Hazelden,theinternationally...ouncedtheleadershipteamforitsnewrecoverycenterinNa...eduledtoopeninlateMarch2010,andwillinitiallyprovid...larrayoffamilyandoutpatientservices. ,, Michael...n,sfacilityinNaples,withBrendaIliff,M.A.,L.A.D.C.,...
(Date:11/23/2009)...liance ProgramSupportsFutureLeadersinSTEMFields ... www.Allia n ceS c holars.org ,,...sident,youcancountusin.Withourcommunity,foundation...EducatetoInnovate,"saidAdolphP.Falcon,SeniorVicePr...rattendingaWhiteHousemeetingtodaywherePresidentOba...
(Date:11/23/2009)...ov.23/PRNewswire/--CortivaInstituteTucsonwillhosta...6from1-3p.m.attheschool,s6390EastBroadwayBlvd.loca...olearnandpracticebasicmassagestrokes. ,, "Massa...sgrowingrightalongwithit,"saidJoannMcMaster,presid...epartmentofLabor,s2009-2010OccupationalOutlookHand...
(Date:11/23/2009).../PRNewswire/--Howistheeconomyaffectingpeople,swell...llnessonWellness&theEconomy,theeconomyismaking...thylifestyleofexerciseanddiettoonethatismoreinward...Thesurvey,smostdramaticfindingwasthechangeinconsum...nalfocusonhealthandwellbeingtotoday,smorerelevantc...
(Date:11/23/2009)...Major medical errors self-reported by American sur...ression. Those findings appear today in the online...ed study included collaborators from Johns Hopkins...he confidential study, nearly 9 percent of U.S. su...the three months prior to being surveyed. Over 70 ...
Breaking Medicine News(10 mins):Health News:Hazelden Names Leadership Team for New Recovery Center in Naples, Florida 2Health News:Alliance Joins President Obama at White House in Commitment to Science, Technology, Engineering, and Math (STEM) Education 2Health News:Cortiva Institute To Host Workshop, Hands-On Opportunity for Prospective Students 2Health News:Being Well Is About Reinvention - Not Health 2Health News:Being Well Is About Reinvention - Not Health 3Health News:Burnout and mental distress strongly related to errors by US surgeons 2
...ine appears safe and may produce beneficial change...with multiple sclerosis, according to an article p... 2007 print issue of Archives of Neurology, one of... brain and spinal cord, according to background in...
...re may be associated with a decreasing peripheral ... their eye pressure remains low overall, according...hthalmology, one of the JAMA/Archives journals. , ...studies reported that lowering intraocular pressur...
...2007, Paying out certain types of government aid i...rmful and often fatal drug binges, according to a ... Public Economics that links the monthly arrival o...Cruz and Texas A&M University suggests that spread...
...disaster strikes, causing structural damage to DNA...ther to help contain the wreckage, scientists at T...r report in the August edition of Cell. , This co...ets for potentially attacking cancer," says senior...
... research from scientists at UT Southwestern Medic...Center underscores the importance of preventing re...ing clues on how typical acid reflux can turn pote...complication of acid reflux called Barretts esopha...
... Surgeons may have a new patient safety tool to st...concerns associated with the current standard bloo...e August issue of the Journal of the American Coll...d bovine thrombin (bThrombin), which is currently ...
Other Medicine News:Health News:DNA vaccine against multiple sclerosis appears safe, potentially beneficial 2Health News:Fluctuating eye pressure associated with visual field deterioration in glaucoma patients 2Health News:Disability payments may spur drug abuse 2Health News:Chromatin remodeling complex connected to DNA damage control 2Health News:Investigators uncover intriguing clues to why persistent acid reflux sometimes turns into cancer 2Health News:Investigators uncover intriguing clues to why persistent acid reflux sometimes turns into cancer 3Health News:New study shows promise in reducing surgical risks associated with surgical bleeding 2
Retinal Lagua Pick: 2.0mm Vertical Notch
Retinal Angled Spatula: Triangular 0.5mm Tip, 4.0mm Surface 110
NitEye The Dry Eye Comforter
...e most comprehensive family of lightweight standar...cision, Glaucoma filtration, and Vitreoretinal use...ith minimal tissue trauma and minimal peripheral c...able in 18, 20, and 20-23Ga tapered designs. Addit...
Medicine Products: